Summary of AngioDynamics Conference Call Company Overview - AngioDynamics is undergoing a transformation to enhance its value by focusing on high-margin, high-growth areas, specifically targeting cardiovascular disease and cancer treatment [3][4] - The company has shifted its portfolio into two reportable segments: med device and med tech, with the latter being the future growth driver [4][25] Financial Performance - The med tech segment has achieved a 25% compound annual growth rate (CAGR) over the last five years [5][25] - For fiscal year 2025, AngioDynamics reported over 8% overall growth, with the med tech segment growing at 20% [26] - Guidance for fiscal year 2026 includes projected revenue between $300 million to $310 million, with med tech expected to grow 12% to 15% year-over-year [30][31] Market Opportunities - The total addressable market (TAM) for the med tech segment in the U.S. is approximately $7 billion, with a global TAM of about $10 billion [7][8] - The company is focusing on venous thromboembolism (VTE) and peripheral arterial disease (PAD) as key growth areas [10][14] Product Segments Med Tech Segment - **Mechanical Thrombectomy**: Products include AlphaVac and AngioVac, with AlphaVac expected to grow significantly due to its advantages over competitors [10][12][60] - **Peripheral Arterial Disease (PAD)**: The AURYON product has grown from zero revenue to over $50 million, with expectations for continued double-digit growth [33][34] - **NanoKnife**: A unique ablation product for treating solid tumors, particularly prostate cancer, with a CPT code expected to enhance market penetration starting January 1 [20][22][24] Growth Strategies - Expansion of the U.S. sales force from 40 to 50 representatives to support growth in the mechanical thrombectomy market [12] - Focus on educating the urology community about NanoKnife's benefits, particularly for patients with intermediate-risk prostate cancer [68][69] Cash Flow and Financial Guidance - The company anticipates a cash burn of $20 million in Q1 of fiscal year 2026 but expects to generate positive cash flow for the remainder of the year [42][44] - The company aims to avoid using its revolver and maintain a safety net for financial stability [43] Risks and Considerations - The company acknowledges the potential impact of tariffs on its operations but believes it can mitigate these effects [46][47] - The competitive landscape includes established players, but AngioDynamics is confident in its product advantages and market strategies [62][65] Conclusion - AngioDynamics is positioned for growth through strategic focus on high-potential markets, innovative products, and a commitment to improving patient outcomes while maintaining financial discipline [28][25]

Core Insights - AngioDynamics reported a strong performance in Q4 FY2025, with total revenue of $80.2 million, reflecting a year-over-year increase of 12.7% driven by growth in both MedTech and med device segments [4][25][45] - The company emphasized the transformational impact of regulatory approvals and market expansion on future revenue potential, despite facing tariff-related headwinds [12][50][63] Financial Performance - Total revenue for FY2025 reached $292.7 million, up 8.1% from the previous year, with MedTech segment revenue growing 19.5% to $126.7 million [9][57] - Adjusted EBITDA for Q4 FY2025 was $3.4 million, an improvement from $1.5 million in Q4 FY2024, indicating margin improvement despite tariff impacts [8][54] - Gross margin for Q4 FY2025 was 52.7%, negatively impacted by tariffs, which reduced margins by 204 basis points [7][51] Segment Performance - MedTech revenue in Q4 FY2025 was $35.8 million, a 22% increase, while med device revenue was $44.4 million, up 6.2% [4][45] - The Auryon platform generated $15.6 million in revenue, growing 19.7% year-over-year, and has shown consistent double-digit growth since its launch [5][45][57] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, increased by 44.7% year-over-year, with AlphaVac revenue growing 60.8% [6][46][57] Guidance and Future Outlook - For FY2026, the company expects net sales between $305 million and $310 million, representing 4%-6% growth, with MedTech sales projected to increase by 12%-15% [10][60] - The company anticipates $15 million in annualized savings by FY2027 through manufacturing transitions, which will enhance operational efficiency [10][42] - Regulatory milestones, including a CPT Category I code for NanoKnife, are expected to drive growth and reimbursement access starting January 2026 [11][37][72] Strategic Initiatives - The company is focused on driving adoption and market share gains across its MedTech platforms while maintaining operational discipline [63][64] - Continued investments in clinical trials and evidence generation are planned to support product adoption and market penetration [11][29][38] - Management has indicated no plans for major acquisitions or divestitures in the near term, focusing instead on executing their current strategy [12][16]